YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
The available CDE acceptance records list 342 drug applications between 13 November 2026 and 19 November 2026 (data as of 23 November 2026). Of these, generic applications numbered 57, covering 40 drug names.
2026/11/13 – 2026/11/19
- New acceptances this week
- 342
- Drugs with new generic filings (by drug name, de-duplicated)
- 40
- Accepted this week, now under review
- 342
DefinitionAcceptance numbers accepted this week that are still on CDE's under-review list at the data cut-off; counted by acceptance date.
Names with a public page are linked.
New acceptances this week
By application type and drug type
342filings, 57 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 180 |
| New drug | 66 |
| Generic | 57 |
| Import | 29 |
| Import re-registration | 9 |
| Unspecified | 1 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 187 |
| TCM | 85 |
| Therapeutic biologic | 61 |
| Biologic | 5 |
| Prophylactic biologic | 4 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
40 drugs with new generic filings; top 10 listed
| # | Drug | New generic filings | Filing companies | Under review, all years |
|---|---|---|---|---|
| 1 | 司美格鲁肽注射液 · No verified English name | 5 | 1 | 99 |
| 2 | Mirogabalin Besilate Tablets | 3 | 2 | 64 |
| 3 | Ambroxol Hydrochloride Oral Solution | 3 | 1 | 49 |
| 4 | Rosuvastatin Calcium and Ezetimibe Tablets (I) | 2 | 2 | 7 |
| 5 | Trazodone Hydrochloride Sustained-release Tablets | 2 | 2 | 22 |
| 6 | 二硫化硒洗剂 · No verified English name | 2 | 1 | 16 |
| 7 | Brexpiprazole Orally Disintegrating Tablets | 2 | 1 | 12 |
| 8 | 恩那度司他片 · No verified English name | 2 | 1 | 2 |
| 9 | Topiramate Tablets | 2 | 1 | 2 |
| 10 | Sildenafil Citrate Tablets | 2 | 1 | 14 |
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
211 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | Henan Pu Rui Pharma Co., Ltd. romanized | 14 | 8 | 0 |
| 2 | Eli Lilly and Company | 9 | 4 | 0 |
| 3 | Novo Nordisk A/S | 6 | 1 | 0 |
| 4 | Boehringer Ingelheim International GmbH | 5 | 2 | 0 |
| 5 | Suzhou Te Rui Pharma Co., Ltd. romanized | 5 | 1 | 5 |
| 6 | Sichuan Sheng Tong Yuan Pharmaceutical Group Co., Ltd. romanized | 4 | 4 | 0 |
| 7 | Beijing Tong Ren Tang Co., Ltd. Tong Ren Tang Pharmaceutical Factory romanized | 4 | 2 | 0 |
| 8 | CSL Behring GmbH | 4 | 1 | 0 |
| 9 | Takeda Manufacturing Austria AG | 4 | 1 | 0 |
| 10 | Chengdu Di Ao Pharmaceutical Group Co., Ltd. romanized | 4 | 1 | 0 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Based on changes in CDE's under-review list
- Entered review this week
- 331
- Left the under-review list this week
- 657
Of these, NMPA published approval-document delivery for 342 (including 338 supplemental applications, not counted as new marketing approvals) and notification delivery for 20; the outcome of the other 295 is to be checked.
Most filings leaving review, by company
| # | Company (first applicant) | Filings | Drugs |
|---|---|---|---|
| 1 | Bai Ji Shen Zhou (Suzhou) Bio Technology Co., Ltd. romanized | 13 | 3 |
| 2 | Mu Dan Jiang Ling Tai Pharma Co., Ltd. romanized | 9 | 9 |
| 3 | AbbVie Inc. | 8 | 1 |
| 4 | Luo Yang Yi Long Pharma Co., Ltd. romanized | 7 | 7 |
| 5 | Shaanxi Dong Tai Pharmaceutical Co., Ltd. romanized | 7 | 7 |
| 6 | Shijiazhuang No.4 Pharmaceutical Co., Ltd. | 7 | 6 |
| 7 | Eli Lilly and Company | 7 | 2 |
| 8 | Novartis Pharma AG | 6 | 4 |
| 9 | Guangdong Tai En Kang Pharmaceutical Factory Co., Ltd. romanized | 6 | 2 |
| 10 | Hybio Pharmaceutical Co.,Ltd. | 6 | 1 |
Most filings entering review, by company
| # | Company (first applicant) | Filings | Drugs |
|---|---|---|---|
| 1 | Henan Pu Rui Pharma Co., Ltd. romanized | 14 | 8 |
| 2 | CISEN PHARMACEUTICAL CO., LTD. | 6 | 3 |
| 3 | Novo Nordisk A/S | 6 | 1 |
| 4 | Shandong Bu Zhang Pharmaceutical Co., Ltd. romanized | 5 | 5 |
| 5 | Boehringer Ingelheim International GmbH | 5 | 2 |
| 6 | Eli Lilly and Company | 5 | 2 |
| 7 | Beijing Tong Ren Tang Co., Ltd. Tong Ren Tang Pharmaceutical Factory romanized | 4 | 2 |
| 8 | Terumo Corporation Kofu Factory | 4 | 1 |
| 9 | Zhongshan Wanhan Pharmaceuticals Co., Ltd. | 4 | 1 |
| 10 | Shenzhen Shi Fan Gu Pharma Co., Ltd. romanized | 4 | 1 |
DefinitionEntered review = acceptance numbers first listed on CDE's under-review list this week, excluding numbers already listed on the record start date (2026/10/22). Left review = acceptance numbers last listed this week and no longer listed at the data cut-off; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.
Class 3 and new-drug acceptances
105 this week
| Accepted | Drug | Applicants |
|---|---|---|
| 2026/11/19Generic · Class 3 | Colistimethate Sodium for InjectionCYHS2602859 | Tianjin Chase Sun Pharmaceutical Co.,Ltd; Sichuan Huiyu Pharmaceutical Co., Ltd. |
| 2026/11/19Generic · Class 3 | 司美格鲁肽注射液 · No verified English nameCYHS2602857 | Suzhou Te Rui Pharma Co., Ltd. romanized; Shenzhen Shi Jian Xiang Biopharmaceutical Co., Ltd. romanized |
| 2026/11/19Generic · Class 3 | 司美格鲁肽注射液 · No verified English nameCYHS2602856 | Suzhou Te Rui Pharma Co., Ltd. romanized; Shenzhen Shi Jian Xiang Biopharmaceutical Co., Ltd. romanized |
| 2026/11/19Generic · Class 3 | 司美格鲁肽注射液 · No verified English nameCYHS2602855 | Suzhou Te Rui Pharma Co., Ltd. romanized; Shenzhen Shi Jian Xiang Biopharmaceutical Co., Ltd. romanized |
| Generic · Class 3 | 司美格鲁肽注射液 · No verified English name | — |
| Generic · Class 3 | 司美格鲁肽注射液 · No verified English name | — |
| 2026/11/19Generic · Class 3 | 盐酸氨酮戊酸颗粒剂 · No verified English nameCYHS2602848 | Shanghai Fu Dan Zhang Jiang Biopharmaceuticals Co., Ltd. romanized |
| 2026/11/19New drug · Class 1 | IBI363 · No verified English nameCXSL2601291 | Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized |
| 2026/11/19New drug · Class 1 | IBI363 · No verified English nameCXSL2601290 | Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized |
| 2026/11/19New drug · Class 1 | IBI3002 · No verified English nameCXSL2601289 | Xin Da Biopharmaceutical (Suzhou) Co., Ltd. romanized |
| 2026/11/19New drug · Class 1 | GenSci161注射液 · No verified English nameCXSL2601288 | Changchun Jin Sai Pharma Co., Ltd. romanized |
| 2026/11/19New drug · Class 1 | GenSci161注射液 · No verified English nameCXSL2601287 | Changchun Jin Sai Pharma Co., Ltd. romanized |
| 2026/11/19New drug · Class 1 | 注射用DB-1421 · No verified English nameCXSL2601286 | Ying En Bio Technology (Shanghai) Co., Ltd. romanized |
| 2026/11/19New drug · Class 1 | 注射用HCB303 · No verified English nameCXSL2601285 | Shanghai Han Ke Bio Co., Ltd. romanized; Guangzhou Han Ke Bio Co., Ltd. romanized |
| 2026/11/19New drug · Class 1 | DA-A-493片 · No verified English nameCXHL2601456 | Chengdu Di Ao Pharmaceutical Group Co., Ltd. romanized |
| 2026/11/19New drug · Class 1 | DA-A-493片 · No verified English nameCXHL2601455 | Chengdu Di Ao Pharmaceutical Group Co., Ltd. romanized |
| 2026/11/19New drug · Class 1 | DA-A-493片 · No verified English nameCXHL2601454 | Chengdu Di Ao Pharmaceutical Group Co., Ltd. romanized |
| New drug · Class 1 | DA-A-493片 · No verified English name | — |
| 2026/11/18Generic · Class 3 | 二硫化硒洗剂 · No verified English nameCYHS2602839 | Anhui Tai Du Biopharmaceuticals Technology Co., Ltd. romanized; Yu Song Yuan Pharma Co., Ltd. romanized |
| 2026/11/18Generic · Class 3 | 二硫化硒洗剂 · No verified English nameCYHS2602838 | Anhui Tai Du Biopharmaceuticals Technology Co., Ltd. romanized; Yu Song Yuan Pharma Co., Ltd. romanized |
| 2026/11/18New drug · Class 1.1 | 龙藤颗粒 · No verified English nameCXZL2600116 | Heilongjiang Sheng Ji Ren Pharma Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | 格斯泮妥塔单抗注射液 · No verified English nameCXSS2600190 | Ming Ji Biopharmaceutical (Beijing) Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | LET003注射液 · No verified English nameCXSL2601284 | He Bo Pharmaceuticals (Shanghai) Co., Ltd. romanized |
| 2026/11/18New drug · Class 2.4 | 注射用重组A型肉毒毒素 · No verified English nameCXSL2601283 | Jiangsu Yao Hai Nuo Xin Bio Technology Co., Ltd. romanized; Yao Hai Nuo Xin Bio Technology (Wuhan) Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | 注射用GB268 · No verified English nameCXSL2601282 | Yi Teng Pharmaceuticals (Zhuhai) Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | ALC01细胞注射液 · No verified English nameCXSL2601281 | Ai Kai Li Yuan Bio Technology (Shanghai) Co., Ltd. romanized |
| 2026/11/18New drug · Class 2.3 | EP-0170T(Ⅰ) · No verified English nameCXHS2600154 | Chengdu Shuo De Pharma Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | TER-2013片 · No verified English nameCXHL2601452 | Bai Ji Shen Zhou (Shanghai) Bio Technology Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | TER-2013片 · No verified English nameCXHL2601451 | Bai Ji Shen Zhou (Shanghai) Bio Technology Co., Ltd. romanized |
| 2026/11/18New drug · Class 1 | BG-75202片 · No verified English nameCXHL2601450 | Bai Ji Shen Zhou (Suzhou) Bio Technology Co., Ltd. romanized |
75 more not listed (at most 30 rows).
For some entries, the drug or company page limits access to the acceptance date, filing number and applicants.
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.